Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZD7OA)

Drug Name

Quaratusugene ozeplasmid Drug Info

Synonyms

GPX-001; CNVN 202

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 1/2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor suppressor candidate 2 (TUSC2)	TTJ8O14	TUSC2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tumor suppressor candidate 2 (TUSC2)	DTT	TUSC2	3.878	5.875	6.032	5.725

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Non-small-cell lung cancer

ICD Disease Classification

2C25.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tumor suppressor candidate 2 (TUSC2)	DTT	TUSC2	3.62E-08	-0.16	-0.72

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04486833) TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Genprex.